Public opinion and medical cannabis policies: examining the role of underlying beliefs and national medical cannabis policies

Harm Reduction Journal

Anne Line Bretteville-Jensen¹  Sharon R. Sznitman² 

[1] Norwegian Institute for Alcohol and Drug Research, Sentrum 0105, Oslo, Norway;School of Public Health, University of Haifa, Eshkol Tower, room 705, Mt. Carmel 3190501, Haifa, Israel

关键词: Cross-national comparison;    Public opinion;    Legalization;    Medical cannabis policies;   

Others  :  1230092
DOI  :  10.1186/s12954-015-0082-x

 received in 2015-09-01, accepted in 2015-10-07,  发布年份 2015

【 摘 要 】

Background

Debate about medical cannabis legalization are typically informed by three beliefs: (1) cannabis has medical effects, (2) medical cannabis is addictive and (3) medical cannabis legalization leads to increased used of cannabis for recreational purposes (spillover effects). We examined how strongly these beliefs are associated with public support for medical cannabis legalization and whether this association differs across divergent medical cannabis policy regimes.

Methods

Robust regression analysis was used to analyse data derived from two nationally representative samples of adults participating in comparable cross-sectional online surveys in one country where medical cannabis smoking is illegal (Norway, n = 2175, 51 % male) and in one country where medical cannabis smoking is legal (Israel, n = 648, 49 % male).

Results

The belief that cannabis has medical benefits was more strongly related to support for medical cannabis legalization than were beliefs about addiction and spillover effects. While the support for medical cannabis legalization was stronger in Israel than in Norway (78 vs. 51 %, p < 0.01), the belief variables had, in general, more impact on the policy stand in Norway.

Conclusion

The belief that cannabis has medical benefits is particularly salient for support for medical cannabis legalization. It is possible that the recent surge in evidence supporting the medical benefits of cannabis will increase the belief about medical benefits of cannabis in the general population which may in turn increase public support for medical cannabis legalization. Results also suggest that once medical cannabis is legalized, factors beyond cannabis-specific beliefs will increasingly influence medical cannabis legalization support. These conclusions are, however, only suggestive as the current study is based on cross-sectional data. Hopefully, future research will be able to capitalize on changes in medical cannabis policies and conduct longitudinal studies that enable an examination of the causal relation between public opinion and medical cannabis policy changes.

【 授权许可】

   
2015 Sznitman and Bretteville-Jensen.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]State medical marijuana laws. National Conference of State Legislatures, Washington, D.C; 2013. http://www. ncsl.org/issues-research/health/state-medical-marijuana-laws.aspx
• [2]Belle-Isle L, Walsh Z, Callaway R, Lucas P, Capler R, Kay R, et al. Barriers to access for Canadians who use cannabis for therapeutic purposes. Int J Drug Policy. 2014, doi:10.1016/j.drugpo.2014.02.009
• [3]Shipton EA, Shipton EE. Should doctors be allowed to prescribe cannabinoids for pain in Australia and New Zealand? Aust N Z J Psychiatry. 2014; 48:310-3.
• [4]Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014; 82:1556-1563.
• [5]Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 2013; 33:195-209.
• [6]Hall W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction. 2015; 110:19-35.
• [7]Wallace MS, Ware MA. Medicinal marijuana: here to stay and time to take responsibility. Clin J Pain. 2015; 4:4.
• [8]ProCon.org. Is medical marijuana more dangerous than legal drugs?, vol. 2015. Santa Monica, CA; 2015. http://medicalmarijuana. procon.org/view.answers.php?questionID=000230 webcite
• [9]Sznitman SR, Zolotov Y. Cannabis for therapeutic purposes and public health and safety: a systematic and critical review. Int J Drug Policy. 2015; 26:20-29.
• [10]Wilkinson ST, D’Souza D. Problems with the medicalization of marijuana. JAMA. 2014; 311:2377-2378.
• [11]Khatapoush S, Hallfors D. “Sending the wrong message”: did medical marijuana legalization in California change attitudes about and use of marijuana? J Drug Issues. 2004; 34:751-770.
• [12]Eddy M. Medical marijuana: review and analysis of federal and state policies, CRS Report for Congress RL33211; 2011. (https://www.fas.org/sgp/crs/misc/RL33211.pdf
• [13]Skretting A. Attitude of the Norwegian population to drug policy and drug-offences. Addiction. 1993; 88:125-131.
• [14]Shanahan M, Gerard K, Ritter A. Preferences for policy options for cannabis in an Australian general population: a discrete choice experiment. Int J Drug Policy. 2014; 25:682-690.
• [15]van der Sar R, Brouwers EPM, van de Goor LAM, Garretsen HFL. The opinion on Dutch cannabis policy measures: a cross-sectional survey. Drugs. 2010; 18:161-171.
• [16]Currie C, Gabhainn SN, Godeau E, Roberts C, Smith R, Currie D, Picket W, Richter M, Morgan A, Barnekow V. Inequalities in young people’s health: international report from the HBSC 2005/2006 survey. WHO Policy Series: Health policy for children and adolescents Issue 4. WHO Regional Office for Europe, Copenhagen; 2008.
• [17]Currie C, Zanotti C, Morgan A, Currie D, de Looze M, Roberts C, Samdal O, Smith ORF, Barnekow V. Social determinants of health and well-being among young people. Health Behaviour in School-aged Children (HBSC) study: international report from the 2009/2010 survey. Health policy for children and adolescents. WHO Regional Office for Europe, Copenhagen; 2012.
• [18]Hibell B, Guttormsson U, Ahlström S, Balakireva O, Bjarnason T, Kokkevi A, Kraus L. The 2011 ESPAD report—substance use among students in 36 European countries. The Swedish Council for Information on Alcohol and Other Drugs (CAN), Stockholm: Sweden; 2011.
• [19]Bar-Hamburger R, Ezrahi Y, Rosiner I, Nirel R. Illegal use of drugs and alcohol in Israel 2009. Seventh national epidemiological survey. Executive summary and tables. Israel Anti-Drug Authority (IADA), Jerusalem, Israel; 2009.
• [20]Hordvin O. The drug situation in Norway 2010. Annual report to the European Monitoring Centre for Drugs and Drug Addiction—EMCDDA. Norwegian Institute for Alcohol and Drug, Oslo, Norway; 2010.
• [21]Nathan G. Regulation of medical cannabis in Israel. Information and Research Center of the Israeli Parliament, Jerusalem, Israel; 2009. http://www. knesset.gov.il/mmm/data/pdf/m02332.pdf
• [22]Landschaft Y. Cannabis for treatment and research—regulatory procedure in Israel. In Cannabis-based drug development, new frontiers in weed medicine. Jerusalem, Israel; 2015.
• [23]Sznitman S, Lewis N. Is cannabis an illicit drug or a medicine? A quantitative framing analysis of Israeli newspaper coverage. Int J Drug Policy. 2015; 26:446-452.
• [24]UCLA: Statistical Consulting Group. Beyond OLS, 4.1.3 Robust regression. In regression with Stata; 2013. http://www.ats.ucla.edu/stat/stata/webbooks/reg/chapter4/statareg4.htm (accessed 23rd of April, 2013).
• [25]Stata Statistical Software: Release 12. StataCorp LP, College Station, TX; 2011.
• [26]Lynch ME, Ware MA. Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials. J Neuroimmune Pharmacol. 2015; 10:293-301.
• [27]Lutge E, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database of Systematic Reviews. 2013: CD005175. DOI: 005110.001002/14651858.CD14005175.pub14651853.
• [28]Parmar JR, Forrest BD, Freeman RA. Medical marijuana patient counseling points for healthcare professionals based on trends in the medical uses, efficacy, and adverse effects of cannabis-based pharmaceutical drugs. Res Social Adm Pharm. in press.
• [29]Belendiuk K, Baldini L, Bonn-Miller M. Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addict Sci Clin Pract. 2015; 10:10. BioMed Central Full Text
• [30]Davis JM, Mendelson B, Berkes JJ, Suleta K, Corsi KF, Booth RE. Public health effects of medical marijuana legalization in Colorado. Am J Prev Med. 2015, Epub ahead of print.
• [31]Boyd CJ, Veliz PT, McCabe SE. Adolescents’ use of medical marijuana: a secondary analysis of monitoring the future data. J Adolesc Health. 2015; 57:241-244.
• [32]D'Amico EJ, Miles JN, Tucker JS. Gateway to curiosity: medical marijuana ads and intention and use during middle school. Psychol Addict Behav. 2015; 1:1.
• [33]Hall W, Weier M. Assessing the public health impacts of legalizing recreational cannabis use in the USA. Clin Pharmacol Ther. 2015; 97:607-615.
• [34]Gates P, Albertella L, Copeland J. The effects of cannabinoid administration on sleep: a systematic review of human studies. Sleep Med Rev. 2014; 18:477-487.
• [35]Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain: a systematic review of randomized trials. Br J Clin Pharmacol. 2011; 72:735-744.
• [36]Machado Rocha FC, StÉFano SC, De CÁSsia Haiek R, Rosa Oliveira LMQ, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl). 2008; 17:431-443.
• [37]Martin-Sanchez E, Furukawa TA, Taylor J, Martin JL. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med. 2009; 10:1353-1368.
• [38]Room R. Legalizing a market for cannabis for pleasure: Colorado, Washington, Uruguay and beyond. Addiction. 2014; 109:345-351.
• [39]Richter KP, Levy S. Big marijuana—lessons from big tobacco. N Engl J Med. 2014; 371:399-401.
• [40]Salomonsen-Sautel S, Min SJ, Sakai JT, Thurstone C, Hopfer C. Trends in fatal motor vehicle crashes before and after marijuana commercialization in Colorado. Drug Alcohol Depend. 2014; 140:137-144.
• [41]Schuermeyer J, Salomonsen-Sautel S, Price RK, Balan S, Thurstone C, Min S-J, Sakai JT. Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003–2011. Drug Alcohol Depend. 2014; 140:145-155.
• [42]Wang G, Roosevelt G, Heard K. Pediatric marijuana exposures in a medical marijuana state. JAMA. 2013; 167:630-633.
• [43]Wang GS, Roosevelt G, Le Lait M-C, Martinez EM, Bucher-Bartelson B, Bronstein AC, Heard K. Association of unintentional pediatric exposures with decriminalization of marijuana in the united states. Ann Emerg Med. 2014; 63:684-689.
• [44]Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2006; 81:103-107.
• [45]Dhalla IA, Mamdani MM, Sivilotti MLA, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. Can Med Assoc J. 2009; 181:891-896.
• [46]Gibson JL, Caldeira GA, Spence LK. Why do people accept public policies they oppose? Testing legitimacy theory with a survey-based experiment. Pol Res Q. 2005; 58:187-201.
• [47]Krosnick JA, Smith WR. Attitude strength. In: Encyclopedia of Human Behavior. RV S, editor. Academic Press, San Diego, CA; 1994: p.279-289.
• [48]Lintonen T, Ahlström S, Metso L. The reliability of self-reported drinking in adolescence. Alcohol Alcohol. 2004; 39:362-368.
• [49]Dolcini MM, Adler NE, Lee P, Bauman KE. An assessment of the validity of adolescent self-reported smoking using three biological indicators. Nicotine Tob Res. 2003; 5:473-474.
• [50]Ramo DE, Liu H, Prochaska JJ. Reliability and validity of young adults’ anonymous online reports of marijuana use and thoughts about use. Psychol Addict Behav. 2012; 26:801-811.